Scientists Develop New Treatment Option for Multidrug-Resistant Infections
Tebipenem pivoxil hydrobromide (SPR994)is a new carbapenem being developed by Spero Therapeutics that is being developed as an oral antimicrobial agent. Such a treatment may facilitate earlier discharge from hospital or the possibility of treating complex infections in the community.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.